CEL-SCI Corporation (CEL-SCI) has initiated clinical study for hospitalised H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins). The study is being led by Principal
PPD has signed an agreement to acquire BioDuro, a drug discovery outsourcing company that provides a broad range of integrated services to biopharmaceutical companies. The acquisition will expand
Genzyme’s Lumizyme failed to receive approval from the FDA for the treatment of pompe disease. The FDA issued a complete response letter (CRL) stating that the agency will
Takeda Pharmaceutical (Takeda) has reported that TAK-438, an acid-related diseases drug, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.
The program will continue to focus on utilizing Ionian’s proprietary isothermal nucleic acid amplification technology, the NEAR Assay, to develop a platform for various global health diseases that
Daiichi Sankyo and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and Ube Industries. Effient helps keep blood platelets from clumping together and developing
NanoString Technologies (NanoString) is collaborating with the Broad Institute of MIT and Harvard, to investigate molecular networks involved in immune response and other important biological processes. Reportedly, the
Formatech has selected Kai Pharmaceuticals (Kai) and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program. Formatech plans to complete
GeneNews has entered into a marketing partnership agreement with Enzo Clinical Labs (Enzo) for the exclusive rights to market ColonSentry in New York and New Jersey. ColonSentry is
Covance has entered into a biomarker alliance and services agreement with Rules-Based Medicine (RBM). As per the terms of the agreement, Covance is expected to use RBM as
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.